NEU neuren pharmaceuticals limited

1.73%

$16.48

Ann: Neuren to capture substantially greater value after Phase 3, page-89

First 89 Last

Share
Profile

Follow
Little T

2,585 Posts.

2738

05/06/20

11:45

Post #: 45056745
Share
Originally posted by hottod: ↑

To make it clear for anyone who might be wondering why I am invested in Neuren as well as Opthea, the list below highlights some advantages NEU has compared with OPT.

NEU is ahead of OPT in its drug development program. It has already commenced the pivotal trial in its lead indication, which is expected to have results in 18 months. OPT has not yet commenced Phase 3 trials and they will likely take at least 3 years.

NEU does not have to fund Phase 3 trials in its two lead indications because of its licensing partnership with Acadia. Opthea will need to raise capital or partner in order to pay for further trials. The lead indication alone (wet AMD) requires two Phase 3 trials, with a total of 1320 patients.

NEU still retains ex-North American rights to trofinetide as well as free access to Acadia’s US regulatory package.

Both of NEU’s lead programs have orphan disease designation in both the US and EU. This confers a minimum 7 year post-approval exclusivity period in the US and 10 years in the EU.

At commencement of Phase 3, the likelihood of approval for a neurology drug is slightly higher than for an ophthalmology drug.

At commencement of Phase 3, the average orphan disease drug has a two in three chance of approval, compared with a one in two chance across all drugs.

Trofinetide does not have to demonstrate superiority to existing approved therapies. There are none. OPT-302 does, as there are already approved therapies.

The FDA has a policy of high patient engagement/consultation and flexibility wrt orphan drugs.

Average annual cost of orphan drugs in United States is $150,000. Annual cost of the leading drugs in wAMD and DME is ~$20,000 - $25,000.

NEU has a second drug asset, which has highly positive pre-clinical data across multiple rare disease and non-rare disease indications. This is already in Phase 1 of clinical development in three rare diseases which have all been granted orphan disease designation. OPT is a single drug asset company.

Expand

Hottod .I agree with all your points but the one I am most excited by is NNZ2591 .I have been told my management and the directors that NNZ2591 is a far superior drug in their opinion than NNZ2566.Acadia is spending a small fortune on NNZ2566 so you would think they are keeping a very close eye on the development of NNZ 2591.
NEU Price at posting: $1.69 Sentiment: Buy Disclosure: Held
18 Upvote

3 Great analysis

Reply

Top Stories

What is going on here? Watch out for DroneShield, Pure Hydrogen, and Nel ASA

Most investors will get this earnings season wrong. Will you?

ASE

Astute delivers high-grade lithium hits at Red Mountain

Rokeby, BHM, more: The 10 hot stocks HotCopper users watchlisted in Week 30

ASX Market Close: Fading miners drag bourse as iron ore price slumps | July 25

SGQ

St George banks $5M from placement to ramp up Araxá Rare Earths Project

Listen: HotCopper Wire Podcast 019 – Dreaming of the 9,000s

FTL

Firetail scoops up untested land around Excelsior – including juicy mineralisation target

RNU

Renascor produces graphite concentrate at Siviour, right on time to meet ex-China demand

Friday's HotCopper trends: Renascor concentrate, Larvotto raise | July 25

First 89 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $16.48		Change -0.290(1.73%)		Mkt cap ! $2.076B

Open	High	Low	Value	Volume
$16.58	$16.74	$16.40	$9.107M	549.9K

Buyers (Bids)

No.	Vol.	Price($)
1	864	$16.43

Sellers (Offers)

Price($)	Vol.	No.
$16.50	1668	1

View Market Depth

No.	Vol.	Price($)
1	864	16.430
1	2500	16.400
1	306	16.300
1	35	16.150
1	50	16.050

Price($)	Vol.	No.
16.620	58	1
16.720	100	1
16.750	300	1
16.890	1266	1
16.950	75	1

Last trade - 16.10pm 25/07/2025 (20 minute delay)

NEU (ASX) Chart

Ann: Neuren to capture substantially greater value after Phase 3, page-89

What is going on here? Watch out for DroneShield, Pure Hydrogen, and Nel ASA

Most investors will get this earnings season wrong. Will you?

Astute delivers high-grade lithium hits at Red Mountain

Rokeby, BHM, more: The 10 hot stocks HotCopper users watchlisted in Week 30

ASX Market Close: Fading miners drag bourse as iron ore price slumps | July 25

St George banks $5M from placement to ramp up Araxá Rare Earths Project

Listen: HotCopper Wire Podcast 019 – Dreaming of the 9,000s

Firetail scoops up untested land around Excelsior – including juicy mineralisation target

Renascor produces graphite concentrate at Siviour, right on time to meet ex-China demand

Friday's HotCopper trends: Renascor concentrate, Larvotto raise | July 25

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Neuren to capture substantially greater value after Phase 3, page-89

Top Stories

What is going on here? Watch out for DroneShield, Pure Hydrogen, and Nel ASA

Most investors will get this earnings season wrong. Will you?

Astute delivers high-grade lithium hits at Red Mountain

Rokeby, BHM, more: The 10 hot stocks HotCopper users watchlisted in Week 30

ASX Market Close: Fading miners drag bourse as iron ore price slumps | July 25

St George banks $5M from placement to ramp up Araxá Rare Earths Project

Listen: HotCopper Wire Podcast 019 – Dreaming of the 9,000s

Firetail scoops up untested land around Excelsior – including juicy mineralisation target

Renascor produces graphite concentrate at Siviour, right on time to meet ex-China demand

Friday's HotCopper trends: Renascor concentrate, Larvotto raise | July 25

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News